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Hydroxyurea and Cardiac Sequelae  
in Children with Sickle Cell Disease 
Moustafa M. Abdel Raheem1, Mohamed A. Abdulrahman2
Cardiac complications in sickle cell disease patients are widely expected. They may be related to iron deposition, anaemia or vascu-
litis. Hydroxyurea is a known drug that decreases haemoglobin (Hb) S levels. The objective of the study was to assess the effect of 
hydroxyurea on cardiac sequelae in children with sickle cell disease. Sixty-five sickle cell disease children were enrolled in the study; 37 
of them were on regular follow up and hydroxurea treatment, whereas 28 were not. All patients underwent echocardiography and 
N-terminal pro-brain natriuretic peptide (NT-proBNP) assay. Plasma levels of NTproBNP were significantly lower in sickle cell patients 
who were on hydroxyurea treatment than in those without this therapy (p=0.03). NTproBNP levels showed significant correlations 
with Hb (r=-0.72, p<0.05) and HbS levels (r=0.54, p<0.05). Significant positive correlations were detected between NTproBNP and 
echocardiography findings (r=0.64, p<0.01) including left ventricular mass index (r=0.78, p<0.01). In conclusion, hydroxyurea may 
reduce cardiac complications in children with sickle cell disease.
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INTRODUCTION
Sickle cell disease (SCD) is a common inherited haemoglo-
bin (Hb) disorder that causes high morbidity in children (1). 
Cardiac complications in children with more severe SCD are 
a common problem (2). Pulmonary hypertension is consid-
ered one of the common risk factors in patients with SCD 
(3). SCD children with only HbS are more prone to vaso-oc-
clusive attacks and other complications. Children who have 
higher levels of HbF may run less severe course (4, 5). SCD 
associated pulmonary hypertension was classified as group 
1 with a subcategory of associated pulmonary hyperten-
sion at the 4th world congress (6).
N-terminal fragment of B-type natriuretic peptide (NTproB-
NP) is the inactive byproduct of pro-BNP cleavage. It is pro-
duced mainly in the left ventricle myocardium and to a less 
extent in other cardiac chambers (7, 8). Many studies indi-
cated that NTproBNP levels had good correlations with pul-
monary hypertension and diastolic dysfunctions (9, 10).
Hydroxyurea is a myelosuppressive agent that is considered 
the only effective drug proven to reduce the frequency of 
painful episodes. It raises the levels of HbF and Hb (11). This 
study was designed to assess the effect of hydroxurea on 
cardiac sequelae in children with SCD.
PATIENTS AND METHODS
We performed a prospective study at Haematology Unit 
and Outpatient Clinic of the Maternity and Children’s Hospi-
tal, Abha, Saudi Arabia, between February 2016 and April 
2017. All procedures performed in our study were in accor-
dance with ethical standards of the Maternity and Children’s 
Hospital Research Committee and the 1964 Helsinki Decla-
ration and its later amendments or comparable ethical stan-
dards. The study was approved by the Hospital Ethics Com-
mittee (REC23/16). A written informed consent was ob-
tained from the parents before the study.
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Study design
Children with confirmed homozygous SCD, by clinical sta-
tus, complete blood cell count, and haemoglobin electro-
phoresis were enrolled in this study. Patients who had suf-
fered events such as pneumonia, heart failure, painful crises, 
vascular accidents, renal or hepatic impairment in the last 
six months before the study, congenital heart disease, dia-
betes mellitus, hypothyroidism and haemoglobinopathies 
other than SCD were excluded.
A total of 65 children with SCD were enrolled in the study. 
They were divided into two groups, i.e. group 1 with 37 pa-
tients (mean age 10±2.3 years) that were on regular hy-
droxyurea treatment with a dose of 20-35 mg/kg/day for at 
least one year and group 2 with 28 patients (mean age 
9±3.4 years) that were not treated with hydroxyurea. Group 
2 patients were not on regular follow up or were referred 
for the first time to our hospital. All patients underwent 
thorough medical history taking and complete examina-
tion, NTproBNP assessment, and echocardiography (ECG) 
evaluation. 
Plasma NT-proBNP assay 
Plasma NT-proBNP was assessed by using a solid double an-
tibody sandwich technique with chemiluminescence im-
munoassay (Immulite 2500, Siemens Healthcare Diagnos-
tics, Deerfield, IL, USA).
Echocardiography evaluation
It was performed using a Vivid 5 echo machine, Alkan Com-
pany 2014 version with a 3-MHz probe including M-mode, 
2 D Doppler and colour Doppler. All patients were assessed 
by the same paediatric cardiologist and measurements 
were calculated by the same machine and the same soft-
ware. Tricuspid regurgitant jet velocity more than 2.5 m/
second (pressure gradient more than 25 mm Hg) indicated 
pulmonary hypertension in the absence of right ventricular 
outflow obstruction. All cardiac dimensions and pressure 
gradient were studied over three cycles. Left ventricular 
mass index (LVMI) was calculated using Devereux formula:
LVMI (g)=0.8{1.04[(IVS+LVDD+LVPW)3-3LVDD]}+0.6 (12).
Data were compared to the corresponding normal values 
for age and sex. ECG was recorded at the same time. 
Statistical analysis
Numerical data were expressed as mean ± standard devia-
tion. Student’s t-test or Mann-Whitney test was used to 
compare numerical variables between the groups. Categor-
ical variables were analysed using χ2 distribution or Fisher 
exact test. Spearman’s correlation test was used to deter-
mine possible correlations between different study param-
eters. The level of statistical significance was defined by 
p<0.05. Statistical analysis was performed by using the SPSS 
version 22 (SPSS, Chicago, IL, USA) software.
RESULTS
A total of 65 children with SCD were enrolled in this study. 
Patients were divided into two groups according to regular 
use of hydroxyurea: group 1 on regular treatment with hy-
droxyurea) and group 2 with no hydroxyurea therapy. Their 
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Age (years)b 11.5±3.2 12.1±1.2 0.21
Haemoglobin (gm/dL)b 8.57±1.0 7.1±1.2 0.01
HbS level (gm/dL)b 6.7±1.7 7.2± 2.1 0.06
HbF level (gm/dL)b 3.4±2.2 1.9±0.8 0.02
Total bilirubin (mg/dL)b 2.02±1.31 3.31±1.4 0.04
Direct bilirubin (mg/dL)b 0.4±0.3 0.49±0.42 0.06
Ferritin (ng/mL)b 570.43±964.32 761.12±1021 0.18
NTproBNP (pg/mL)b 84.20±16.5 112.59±20.2 0.001
aNumber (%); bvalues are means ± SD.




SPAPa 16.5±8.3 mm Hg 29.5±11.4 mm Hg 0.02*
EF (%)a 63.4±22.6 60.9±28.4 0.3
FS (%)a 41.4±13.6 37.1±15.3 0.4




avalues are means ± SD; *p value significant; SPAP = systolic pulmonary 
artery pressure; EF = ejection fraction; FS = fractional shortening;  
LVMI = left ventricular mass index
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clinical and laboratory characteristics are shown in Table 1. 
As shown in Table 1, there was no significant between-
group difference according to sex distribution, age, HbS, 
direct bilirubin and serum ferritin. Hb, HbF and total biliru-
bin levels were significantly higher in group 1 in compari-
son to group 2 (p<0.03, p<0.02 and p<0.04, respectively), 
whereas NTproBNP was significantly lower in group 1 in 
comparison to group 2 (p<0.03).
Systolic pulmonary artery pressure (SPAP) and LVMI were 
significantly lower in group 1 than in group 2 patients 
(p=0.02 and p=0.04, respectively). The ECG findings in the 
study groups are shown in Table 2.
Our results demonstrated a significant negative correlation 
between NTproBNP levels and Hb level (r=-0.72, p<0.05) 
and significant positive correlations between NTproBNP 
level and HbS levels (r=0.54, p<0.05). Significant positive 
correlations were detected between NTproBNP and ECG 
findings including SPAP (r=0.64, p<0.01) and LVMI (r=0.78, 
p<0.01), as shown in Table 3.
DISCUSSION
As a multisystem disorder, SCD may affect many organs in-
cluding the heart. Cardiac involvement may be presented 
in many features with different pathologies (13). Hydroxy-
urea seems to control the incidence of acute vaso-occlusive 
attacks and its complications and improves exercise toler-
ance (11, 14). Results of our study showed that both total 
Hb and HbF levels were significantly higher in group 1 pa-
tients who regularly received hydroxyurea while total biliru-
bin and serum ferritin were significantly lower than in group 
2, which was consistent with the studies evaluating effec-
tiveness of the use of hydroxyurea in SCD patients (15, 16). 
NTproBNP levels were statistically significantly lower in 
treated patients. Shinichi et al. recorded positive correlation 
between NTproBNP and severity of anaemia in SCD chil-
dren (17). Higher levels of NTproBNP indicate greater vol-
ume and pressure overload on cardiac chambers (18). Many 
studies showed that elevated cardiac output was common-
ly associated with SCD (19, 20). Cardiac output in chronic 
anaemic patients may be elevated as a consequence of the 
renin-angiotensin-aldosterone system activation and sym-
pathetic hyperactivity, and this myocardium overload may 
lead to increased NTproBNP release (21, 22). Chronic severe 
anaemia induces myocardial ischemia on top of persistent 
hypoxia, which may cause vasodilatation with low systemic 
vascular resistance mediated by endothelial nitric oxide 
(23). Group 2 patients showed significantly higher SPAP and 
LVMI than those group 2 patients, which reflected less car-
diac involvement in the patients regularly treated with hy-
droxyurea. These results regarding the non treated group 
are in agreement with the studies by Kato et al. and Pank-
anker et al. (24, 25) that report elevated SPAP in patients with 
progressive SCD. The same results were noticed by Shinichi 
et al. (17). Other mechanisms may be involved in cardiac af-
fection in SCD patients including iron overload, myocardial 
ischemia mediated through hypoxia, anaemia and rarely 
red blood cell sickling (18). Our results showed that LVMI 
was significantly elevated in the non treated group. Accord-
ing to Devereux formula, LVMI elevation reflects the incre-
ment of interventricular septum, left ventricular posterior 
wall and left ventricular dimension in diastole (12). These 
parameters are affected by many factors in SCD patients in-
cluding Hg and HgS levels. In previous studies, there was 
significant correlation between HbS levels and left ventricu-
lar hypertrophy (26, 27). Our hydroxyurea treated patients 
showed higher Hb levels and lower LVMI. These findings are 
in agreement with many previous studies (27, 28). Accord-
ingly, regular use of hydroxyurea is considered a prophylac-
tic treatment against left ventricular hypertrophy.
The benefits recorded for the use of hydroxyurea in SCD pa-
tients include its efficacy in reducing multiorgan damage 
manifestations in children including hypoxemia, pulmonary 
hypertension, proteinuria and glomerular injury, which may 
lead to decrement of myocardial load (15). The present 
study showed significant positive correlations of NTproBNP 
and echocardiographic SPAP and LVMI. Many studies in SCD 
patients suggest that NTproBNP is a good predictor of tri-
cuspid regurgitation and elevated pulmonary pressure (8, 
10, 29). Other studies have reported elevated serum NT-
proBNP levels in disease progression and development of 
heart failure, and suggest that NTproBNP may be of prog-
nostic value for left ventricular diastolic dysfunction These 
findings indicate that poor control of SCD children may lead 
to pulmonary hypertension and development of impaired 
diastolic functions, indicating the benefit of using hydroxy-
urea to decrease these sequelae (17, 30, 31).
Our study limitation was the small cohort of patients, which 
was not sufficient to enable us to give firm statement about 
the use of hydroxyurea. Additional studies are necessary.
CONCLUSION
The current study suggested that patients with SCD are at a 
risk of cardiac involvement and regular hydroxyurea treat-
ment may reduce this risk.
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S A Ž E T A K
Hidroksiureja i srčane posljedice  
u djece s bolešću srpastih stanica
M. M. Abdel Raheem, M. A. Abdulrahman
Srčane komplikacije su vrlo vjerojatne u bolesnika s bolešću srpastih stanica, a mogu biti povezane s odlaganjem željeza, anemijom 
ili vaskulitisom. Hidroksiureja je lijek koji snižava razine hemoglobina (Hb) S. Cilj istraživanja bio je procijeniti učinak hidroksiureje na 
srčane posljedice u djece s bolešću srpastih stanica. U studiju je bilo uključeno 65 djece s bolešću srpastih stanica, od kojih je 37 bilo 
na terapiji hidroksiurejom uz redovito praćenje, a preostalih 28 nije primalo ovu terapiju. U svih bolesnika učinjena je ehokar diografija 
i test NT-proBNP. Razine NT-proBNP u plazmi bile su značajno niže u bolesnika s bolešću srpastih stanica koji su primali terapiju 
 hidroksiurejom nego u onih bez ove terapije (p=0,03). Razine NT-proBNP pokazale su značajnu korelaciju s razinama Hb (r=-0,72, 
p<0,05) i HbS (r=0,54, p<0,05). Značajna pozitivna korelacija utvrđena je između NT-proBNP i ehokardiografskih nalaza (r=0,64, 
p<0,01) uključujući indeks mase lijeve klijetke (r=0,78, p<0,01). Zaključno, hidroksiureja može smanjiti srčane komplikacije kod djece 
s bolešću srpastih stanica.
Ključne riječi: HIDROKSIUREJA; SRCE; DJECA; ANEMIJA, BOLEST SRPASTIH STANICA
